Edition:
United Kingdom

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

16.14USD
20 Apr 2018
Change (% chg)

$0.10 (+0.62%)
Prev Close
$16.04
Open
$16.00
Day's High
$16.18
Day's Low
$15.77
Volume
111,911
Avg. Vol
223,874
52-wk High
$48.74
52-wk Low
$15.74

Select another date:

Tue, Apr 17 2018

BRIEF-Five Prime Therapeutics Appointed Linda Rubinstein As Interim CFO

* FIVE PRIME THERAPEUTICS INC - ON APRIL 13 APPOINTED LINDA RUBINSTEIN AS INTERIM CHIEF FINANCIAL OFFICER - SEC FILING

BRIEF-Five Prime Therapeutics To Close Bladder Cancer Cohort Of Its Phase 1 FPA144-001 Trial

* TO CLOSE BLADDER CANCER COHORT OF PHASE 1 TRIAL EVALUATING BEMARITUZUMAB TREATING PATIENTS WHOSE TUMORS OVEREXPRESS FGFR2B PROTEIN

BRIEF-Personal Genome Diagnostics enteres into a collaboration with Five Prime Therapeutics

* CO INTENDS TO SUBMIT ASSAY FOR REGULATORY APPROVAL, COMMERCIALIZE IN U.S., EUROPE, JAPAN, CHINA, OTHER COUNTRIES

BRIEF-Five Prime Therapeutics Starts Patient Dosing In Phase 1 Trial In Antibody Study

* FIVE PRIME THERAPEUTICS INITIATES PATIENT DOSING IN PHASE 1 TRIAL OF NOVEL FIRST-IN-CLASS B7-H4 ANTIBODY FPA150 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Five Prime Therapeutics Announces Executive Change

* ‍BELSKY WILL CONTINUE IN HIS CURRENT ROLE UNTIL APRIL 6, 2018​ Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Five Prime Reports Q4 Loss Per Share $1.04

* FIVE PRIME ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Five Prime Therapeutics Announces $25 Mln Payment By Bristol-Myers Squibb

* FIVE PRIME THERAPEUTICS ANNOUNCES $25 MILLION PAYMENT BY BRISTOL-MYERS SQUIBB FOR CABIRALIZUMAB DEVELOPMENT MILESTONE

BRIEF-Five Prime Announces Pricing Of Upsized Public Offering Of Common Stock

* FIVE PRIME ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Five Prime Announces Proposed Public Offering Of Common Stock

* FIVE PRIME ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb

* FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME

Select another date: